MannKind Corporation · 1 month ago
Marketing Intern- FUROSCIX
Burlington, MA
Internship
Hybrid
InternMannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. The Marketing Intern will support the Marketing team by contributing to the FUROSCIX Brand Team, gaining hands-on experience in real-world pharma marketing projects.
BiotechnologyHealthcarePharmaceuticalHealth Care
No H1B
Responsibilities
Help develop best practice/innovative machine learning and AI tactical assessments for leads/media/social campaigns that are aligned with pharma guidelines
Identifying novel ways to reach Healthcare Providers (HCPs) and Patients through digital channels
Conduct market landscape assessments as well as competitive reviews of HCP marketing tactics to identify new opportunities to leverage
Evaluating cost‑efficient strategies to support the development of tactics that address common hurdles to further FUROSCIX adoption
Assisting in the creation of a clear, simple, and unified framework to track and monitor the performance of key marketing initiatives
Mapping emerging customer consumption trends and helping determine what needs to be built today to support future prescribing and buying behaviors
Other duties as assigned
Qualification
Required
Currently pursuing a Bachelor's or Master's degree in Business, Marketing
Analytical competencies
Ability to think outside of the box
Ability to both conceive ideas but also execute seamlessly
Strong ability to spot trends with limited information and conceive new ways to prepare for future trends
A reliable commute or the intention to find temporary housing before starting the internship
Candidates who do not require visa sponsorship, including those with a student visa
Preferred
Interest or experience in Digital Marketing
Preferably within 1-2 years of graduation or pursuing a post-grad program
Company
MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions.
Founded in 2001
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$480MKey Investors
United TherapeuticsBlackstone GroupDeerfield Capital Management
2026-05-06Post Ipo Equity· $5M
2025-08-06Post Ipo Debt· $75M
2021-03-02Post Ipo Debt· $200M
Leadership Team
Michael Castagna
Chief Executive Officer
Christopher Prentiss
Chief Financial Officer
Recent News
Investing.com
2026-05-06
2026-05-06
Company data provided by crunchbase